Loading organizations...
Schrödinger develops a sophisticated physics-based computational platform that accelerates drug discovery and materials design. This integrated suite of software tools leverages advanced algorithms and high-performance computing to simulate molecular interactions with high accuracy, enabling researchers to predict properties, optimize compounds, and design novel therapeutics and materials more efficiently. The platform’s capabilities span across various stages of the discovery pipeline, from lead identification to preclinical development.
The company was founded in 1990 by Richard A. Friesner, a chemistry professor, and William A. Goddard III. Their foundational insight stemmed from recognizing the transformative potential of applying rigorous physics and chemistry principles through computational methods to address complex challenges in life sciences and materials science, an approach distinct from traditional empirical experimentation. This academic expertise formed the bedrock of Schrödinger’s scientific methodology.
Schrödinger’s products serve a broad client base, including pharmaceutical and biotechnology companies, as well as academic and governmental institutions engaged in scientific research and development. The company’s overarching mission is to enhance human health and improve quality of life by fundamentally transforming how therapeutics and advanced materials are discovered and developed, pushing the boundaries of what is possible through computational innovation.
Schrödinger has raised $177.0M across 4 funding rounds.
Key people at Schrödinger.
Schrödinger was founded in 1990 by William Goddard (Co-Founder) and Richard Friesner (Co-Founder).
Schrödinger has raised $177.0M in total across 4 funding rounds.
Schrödinger was founded in 1990 by William Goddard (Co-Founder) and Richard Friesner (Co-Founder).
Schrödinger has raised $177.0M in total across 4 funding rounds.
Schrödinger's investors include 01 Ventures, 305 Ventures, Activant Capital, Ambridge Capital, Ballistic Ventures, Bombas, Builders VC, CP Ventures, Craft Ventures, CRV, E-Merge, Formic Ventures.
Schrödinger has raised $177.0M across 4 funding rounds. Most recently, it raised $25.0M Series E in May 2019.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 1, 2019 | $25M Series E | — | 01 Ventures, 305 Ventures, Activant Capital, Ambridge Capital, Ballistic Ventures, Bombas, Builders VC, CP Ventures, Craft Ventures, CRV, Emergence Capital, Formic Ventures, Foundation Capital, Founders Fund, Foundry Group, General Atlantic, Long Ventures Partners, OAK HC/FT, ONE WAY Ventures, Pario Ventures, Sequoia Capital, Soma Capital, Streamlined Ventures, Team Ignite Ventures, The HIT Forge, Tribe Capital, UpHonest Capital, Wave Financial, WestCap, Aaron Vandevender, Andrus Purde, Evan LEE, Indrek Kasela, Khaled Helioui, Martin Villig, Märt Kelder, Preetha Parthasarathy, Russell Cook, Ryan Duranso, Sung HO Choi | Announced |
| Jan 1, 2019 | $110M Series E | — | Qiming Venture Partners | Announced |
| Jun 1, 2015 | $22M Series D | — | Galaxy Digital, Social Starts | Announced |
| Dec 1, 2012 | $20M Series C | — | — | Announced |
Schrödinger, Inc. (Nasdaq: SDGR) is a New York-based technology company specializing in physics-based computational software for drug discovery and materials science. It builds advanced molecular simulation platforms that predict molecular behaviors with experimental accuracy, enabling pharmaceutical, biotech, chemical, energy, and academic users to accelerate R&D, cut costs, and design novel drugs and materials.[1][2][5][6]
The platform serves biotech firms, pharma companies, materials researchers, and academics by solving the inefficiencies of traditional trial-and-error methods—reducing synthesis needs through in silico testing of billions of candidates. With over 900 employees across offices in New York, Boston, Portland, and San Diego, Schrödinger shows strong growth momentum, including cloud migration for scalable computing and an internal therapeutics group targeting validated drug targets.[3][5]
Founded in 1990 in New York by computational chemists Richard A. Friesner and William A. Goddard III, Schrödinger emerged from the need for accurate, physics-driven tools to model molecular systems—a novel concept at the time when drug discovery relied heavily on physical experiments.[1][2]
The idea stemmed from academic frustrations with imprecise simulations; early traction came swiftly with the first major software sale to Brookhaven National Laboratory in 1992, validating their approach. Backed by venture capital and a notable 2010 investment from Bill Gates, the company evolved from software licensing in life sciences and materials research to a public entity, investing over 30 years in R&D to refine its platform.[1][5]
Schrödinger rides the AI and computational biology wave, transforming drug discovery from intuition-driven to data-accelerated processes amid rising R&D costs and failure rates. Its timing aligns with explosive growth in biotech computing needs, fueled by market forces like personalized medicine, sustainable materials demand, and cloud scalability.[5][6]
By partnering with pharma giants and enabling faster iterations, it influences the ecosystem—lowering barriers for novel therapeutics (e.g., via its own drug programs) and materials innovation in energy and consumer goods, positioning it as a key enabler in the convergence of physics, AI, and life sciences.[2][6]
Schrödinger is poised to expand its therapeutics pipeline and materials applications, leveraging AI integrations and cloud power to tackle high-value targets with genetic validation. Trends like multimodal AI-drug design and green chemistry will propel it, potentially amplifying influence through more in-house drugs and ecosystem partnerships.
As molecular discovery barriers crumble, Schrödinger exemplifies how physics-based tech unlocks tomorrow's innovations—echoing its 1990 vision in a public, scaled reality.[1][6]
Key people at Schrödinger.
